BG100517A - Combination of bisphosphonates and growth hormone secretagogues - Google Patents

Combination of bisphosphonates and growth hormone secretagogues

Info

Publication number
BG100517A
BG100517A BG100517A BG10051796A BG100517A BG 100517 A BG100517 A BG 100517A BG 100517 A BG100517 A BG 100517A BG 10051796 A BG10051796 A BG 10051796A BG 100517 A BG100517 A BG 100517A
Authority
BG
Bulgaria
Prior art keywords
bisphosphonates
combination
growth hormone
hormone secretagogues
secretagogues
Prior art date
Application number
BG100517A
Other languages
Bulgarian (bg)
Inventor
Barry Gertz
Gideon Rodan
Roy Smith
Matthew Wyvratt
Arthur Patchett
Original Assignee
Merck & Co. Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co. Inc. filed Critical Merck & Co. Inc.
Publication of BG100517A publication Critical patent/BG100517A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретението се отнася до бисфосфонати в комбинация със стимулатори на секрецията на соматотропнияхормон, чрез които се намаляват вредните последици от остеопорозата у възрастни пациенти.The invention relates to bisphosphonates in combination with somatropin hormone secretion stimulators, which reduce the harmful effects of osteoporosis in adult patients.

BG100517A 1993-10-19 1996-04-18 Combination of bisphosphonates and growth hormone secretagogues BG100517A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13929693A 1993-10-19 1993-10-19
US25909194A 1994-06-13 1994-06-13
PCT/US1994/011912 WO1995011029A1 (en) 1993-10-19 1994-10-18 Combination of bisphosphonates and growth hormone secretagogues

Publications (1)

Publication Number Publication Date
BG100517A true BG100517A (en) 1996-11-29

Family

ID=26837073

Family Applications (1)

Application Number Title Priority Date Filing Date
BG100517A BG100517A (en) 1993-10-19 1996-04-18 Combination of bisphosphonates and growth hormone secretagogues

Country Status (16)

Country Link
EP (1) EP0813414A4 (en)
JP (1) JPH09504525A (en)
KR (1) KR960705575A (en)
CN (1) CN1136278A (en)
AU (1) AU8083694A (en)
BG (1) BG100517A (en)
BR (1) BR9407869A (en)
CA (1) CA2173333A1 (en)
CZ (1) CZ109196A3 (en)
FI (1) FI961681A (en)
HU (1) HUT75224A (en)
LV (1) LV11432B (en)
NO (1) NO961536L (en)
PL (1) PL314003A1 (en)
SK (1) SK49796A3 (en)
WO (1) WO1995011029A1 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US20020111461A1 (en) 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
DE69533991T2 (en) * 1995-05-29 2006-04-13 Pfizer Inc. DIPEPTIDES THAT STIMULATE THE DISTRIBUTION OF GROWTH HORMONES
WO1997015191A1 (en) * 1995-10-27 1997-05-01 Merck & Co., Inc. Wet granulation formulation of a growth hormone secretagogue
ATE334394T1 (en) 1995-12-13 2006-08-15 Merck & Co Inc TEST METHODS FOR THE SECRETION RECEPTORS OF GROWTH HORMONES
US6531314B1 (en) 1996-12-10 2003-03-11 Merck & Co., Inc. Growth hormone secretagogue receptor family
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (en) * 1996-02-28 1997-06-26 Inc Pfizer COMBINED THERAPY FOR OSTEOPOROSIS
CN1220609A (en) * 1996-05-31 1999-06-23 诺沃挪第克公司 Growth hormone component and bone anti-resorptive agent in cyclic (coherence) treatment of osteoporosis
WO1998018815A1 (en) * 1996-10-25 1998-05-07 Merck & Co., Inc. Convergent process for the preparation of a growth hormone secretagogue
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
ZA987385B (en) * 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
US6211174B1 (en) * 1997-10-31 2001-04-03 Merck & Co., Inc. Naphtho-fused lactams promote release of growth hormone
IT1296495B1 (en) * 1997-11-21 1999-06-25 Prodotti Antibiotici Spa USE OF BISPHOSPHONATES IN THE PREPARATION OF PHARMACEUTICAL FORMS FOR INTRAMUSCULAR ADMINISTRATION
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
WO2000002919A1 (en) 1998-07-13 2000-01-20 Merck & Co., Inc. Growth hormone secretagogue related receptors and nucleic acids
US6645726B1 (en) 1998-08-10 2003-11-11 Merck & Co., Inc. Canine growth hormone secretagogue receptor
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
WO2000010565A1 (en) * 1998-08-18 2000-03-02 Eli Lilly And Company Growth hormone secretagogues
AR013994A1 (en) * 1998-10-30 2001-01-31 Gador Sa PROCEDURE AND PREPARATIONS THAT SELECTIVELY MODULATE THE FUNCTION OF THE OSTEOBLASTO FOR THE PREVENTION AND TREATMENT OF FRAGILIZING OSTEOPATHIES.
AU1525700A (en) * 1998-11-19 2000-06-05 Board Of Trustees Of The University Of Arkansas, The Increasing bone strength with selected bisphosphonates
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
CN1372468A (en) * 1999-06-02 2002-10-02 宝洁公司 Oral preparations of etidronate disodium
DE60140285D1 (en) 2000-05-31 2009-12-10 Pfizer Prod Inc Use of growth hormone secretagogues to promote the mobility of the digestive tract
US6548042B2 (en) 2000-08-07 2003-04-15 Arstad Erik Bis-phosphonate compounds
US7560490B2 (en) * 2001-01-23 2009-07-14 Gador S.A. Composition comprising bisphosphonates for prevention and/or treatment of metabolic diseases of bones, process for preparing such composition and use thereof
US7125840B2 (en) 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
ES2271557T3 (en) 2002-04-09 2007-04-16 Eli Lilly And Company DIPEPTIDIC SECRETAGOGS OF THE HORMONE OF GROWTH.
GB0213715D0 (en) 2002-06-14 2002-07-24 Syngenta Ltd Chemical compounds
ES2394782T3 (en) * 2003-05-07 2013-02-05 Osteologix A/S Composition with strontium and vitamin D for the prophylaxis and / or treatment of cartilage and / or bone conditions
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
MX2007002033A (en) 2004-08-19 2007-04-26 Vertex Pharma Modulators of muscarinic receptors.
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
NZ555444A (en) 2004-11-29 2011-01-28 Vertex Pharma Modulators of muscarinic receptors
WO2007076070A2 (en) 2005-12-22 2007-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
AU2007221220A1 (en) 2006-02-22 2007-09-07 Vertex Pharmaceuticals Incorporated Spiro condensed piperidnes as modulators of muscarinic receptors
JP2009527568A (en) 2006-02-22 2009-07-30 バーテックス ファーマシューティカルズ インコーポレイテッド Modulator of muscarinic receptor
CU23558A1 (en) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech COMPOUNDS ANALOG TO THE PEPTIDIC SECRETAGOGS OF THE GROWTH HORMONE
US7858790B2 (en) 2006-06-29 2010-12-28 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
WO2008021375A2 (en) 2006-08-15 2008-02-21 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
JP2010501561A (en) 2006-08-18 2010-01-21 バーテックス ファーマシューティカルズ インコーポレイテッド Modulator of muscarinic receptor
EA200901077A1 (en) 2007-02-09 2010-04-30 Транзим Фарма, Инк. MACRO CYCLIC MODULATORS OF THE GREEL RECEPTOR AND THEIR APPLICATION
EP2155769B1 (en) 2007-05-04 2012-06-27 Katholieke Universiteit Leuven KU Leuven Research & Development Tissue degeneration protection
MX2010003373A (en) 2007-10-03 2010-04-30 Vertex Pharma Modulators of muscarinic receptors.
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
KR20160147007A (en) 2014-05-30 2016-12-21 화이자 인코포레이티드 Carbonitrile derivatives as selective androgen receptor modulators
JP2021526792A (en) 2018-06-06 2021-10-11 マサチューセッツ インスティテュート オブ テクノロジー Circular RNA for translation in eukaryotic cells
SG11202112922WA (en) 2019-05-22 2021-12-30 Massachusetts Inst Technology Circular rna compositions and methods
EP3920976B1 (en) 2019-12-04 2023-07-19 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU568433B2 (en) * 1984-04-30 1987-12-24 Procter & Gamble Company, The Treating osteoporosis
AU569391B2 (en) * 1984-04-30 1988-01-28 Procter & Gamble Company, The Treating osteoporosis
SK282166B6 (en) * 1992-12-11 2001-11-06 Merck & Co., Inc. Spiropiperinde derivatives, method for their preparation and pharmaceutical preparation containing them
US5284841A (en) * 1993-02-04 1994-02-08 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5434261A (en) * 1993-07-26 1995-07-18 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5545735A (en) * 1993-10-04 1996-08-13 Merck & Co., Inc. Benzo-Fused Lactams promote release of growth hormone

Also Published As

Publication number Publication date
NO961536L (en) 1996-06-18
HU9601013D0 (en) 1996-06-28
FI961681A (en) 1996-06-12
AU8083694A (en) 1995-05-08
KR960705575A (en) 1996-11-08
HUT75224A (en) 1997-04-28
PL314003A1 (en) 1996-08-05
NO961536D0 (en) 1996-04-18
LV11432B (en) 1996-12-20
JPH09504525A (en) 1997-05-06
CZ109196A3 (en) 1996-10-16
CN1136278A (en) 1996-11-20
WO1995011029A1 (en) 1995-04-27
LV11432A (en) 1996-08-20
FI961681A0 (en) 1996-04-17
EP0813414A4 (en) 1999-07-21
BR9407869A (en) 1996-10-29
SK49796A3 (en) 1997-05-07
EP0813414A1 (en) 1997-12-29
CA2173333A1 (en) 1995-04-27

Similar Documents

Publication Publication Date Title
BG100517A (en) Combination of bisphosphonates and growth hormone secretagogues
DE10199020I2 (en) Galanthamine or its analogues for the treatment of Alzheimer's disease.
DE3484933D1 (en) IMPLANT FOR FASTENING DENTAL PROSTHESES.
UA39158C2 (en) derivatives of N4-oxycarbonyl- 5'-deoxy-5-fluorocytidine and pharmaceutical preparation based thereon
EP0680525A1 (en) Fibres.
NO167122C (en) IMPLANT TREATMENT.
BG100960A (en) Dosage forms for controlled release of azitromycin
UA43378C2 (en) Composition for treating the respiratory distress- syndrome of the newborns and respiratory distress- syndrome of the adult
ZA841597B (en) Human nerve growth factor by recombinant technology
DE3466879D1 (en) Cyclic pentapeptides displaying somatostatin antagonism and method of treatment of mammals therewith
DE3775371D1 (en) THIGH NECK PROSTHESIS.
DE69316013D1 (en) USE OF PHOSPHINATE FOR TREATING OSTEOPOROSIS
EP0610286A4 (en) Recombinant immunotoxins.
MX9701187A (en) Novel n-substituted naphthofused lactams.
HK1053264A1 (en) Phosphonate analogues of mannose-6-phosphate and their use in the treatment of wounds and fibrotic disorders.
GR78135B (en)
ES8707488A1 (en) Biologically active ketone derivative, preparation and use.
AU5732190A (en) Glycoprotein hormone receptor molecules
BG102667A (en) Diosgenine-containing composition
ZA878182B (en) Enhancement of prazosin
ATE291918T1 (en) COMBINATION THERAPY FOR THE TREATMENT OF TUMORS
EP1056458A4 (en) Method for the treatment of pain, including chronic and female specific pain
DE3485580D1 (en) ALGORITHM FOR THE ADMINISTRATION OF INSULIN.
DE59104412D1 (en) Dynamic reduction rail for the therapy of forefoot adduction.
GR3001850T3 (en) Expellants of phytopathogenic microbes